Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy

[D.ap]

Abstract

Immune checkpoint blockade therapy is a powerful treatment strategy for many cancer types. Many patients will have limited responses to monotherapy targeted to a single immune checkpoint. Both inhibitory and stimulatory immune checkpoints continue to be discovered. Additionally, many receptors previously identified to play a role in tumor formation and progression are being found to have immunomodulatory components. The success of immunotherapy depends on maximizing pro-anti-tumor immunity while minimizing immunosuppressive signaling. Combining immune checkpoint targeted approaches with each other or with other receptor targets is a promising schema for future therapeutic regimen designs.

Keywords: immune checkpoint, combination therapy, receptor targets

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337574/